A total of 63.8% (60/94) patients used 3∼5 types of previous ITP medication before ELT treatment, including intravenous immunoglobulin (IVIG), corticosteroids, rituximab, recombinant human TPO (rhTPO), other TPO-RAs, or additional ITP medications. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.